Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-CFB in Healthy Volunteers and IgA Nephropathy
NCT06209177Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial of ARO-CFB in IgA nephropathy (IgAN) (2 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs). Started Apr 2024; status: completed.
02
Drugs
ARO-CFB
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06209177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209177.